

In the Claims

1-8. (Canceled)

30. (Previously presented) An isolated and purified nucleic acid sequence encoding a 30 kD *Ostertagia ostertagi* protein or a part of said nucleic acid sequence that encodes an immunogenic fragment of said protein, said nucleic acid sequence or said part thereof having at least 85% homology with the nucleic acid sequence of the *Ostertagia ostertagi* protein gene as depicted in SEQ ID NO: 9.

31. (Previously presented) A recombinant DNA molecule comprising a nucleic acid sequence according to claim 30, under the control of a functionally linked promoter.

32. (Previously presented) A live recombinant carrier, comprising:

a nucleic acid sequence according to claim 30.

33. (Previously presented) A recombinant host cell, comprising:

a nucleic acid sequence according to claim 30.

4

Attorney Docket: I-2002.015 US  
Customer No.: 31846  
USSN: 10/527,771

34. (Previously presented) An isolated and purified 30 kD *Ostertagia ostertagi* protein or an immunogenic fragment of said protein, wherein said protein or immunogenic fragment thereof has a sequence homology of at least 90% to the amino acid sequence as depicted in SEQ ID NO: 10.

35. (Previously presented) An *Ostertagia ostertagi* protein or an immunogenic fragment of said protein, wherein said protein or immunogenic fragment is encoded by a nucleic acid sequence according to claim 30.

36. (Previously presented) A vaccine for combating *Ostertagia ostertagi* infection, comprising:

at least one *Ostertagia ostertagi* protein or an immunogenic fragment of said protein according to claim 34 and a pharmaceutically acceptable carrier.

37. (Previously presented) A vaccine for combating *Ostertagia ostertagi* infection, comprising:

the nucleic acid sequence according to claims 30, and a pharmaceutically acceptable carrier.

38. (Previously presented) A vaccine for combating *Ostertagia ostertagi* infection, comprising:

Attorney Docket: I-2002.015 US  
Customer No.: 31846  
USSN: 10/527,771

5

the recombinant host cell according to claim 33 and a pharmaceutically acceptable carrier.

39. (Previously presented) A vaccine for combating *Ostertagia ostertagi* infection, comprising:

the live recombinant carrier according to claim 32 and a pharmaceutically acceptable carrier.

40. (Previously presented) The vaccine according to claim 36, further comprising an adjuvant.

41. (Previously presented) The vaccine according to claim 36, further comprising:

an additional antigen derived from a virus or micro-organism pathogenic to cattle, an antibody against said antigen or genetic information encoding said antigen and/or a pharmaceutical component.

42. (Previously presented) The vaccine according to claim 41, wherein said virus or microorganism pathogenic to cattle is selected from the group of Bovine Herpesvirus, bovine Viral Diarrhea virus, Parainfluenza type 3 virus, Bovine Paramyxovirus, Foot and Mouth Disease virus, *Pasteurella haemolytica*, Bovine Respiratory Syncytial Virus, *Theileria* sp., *Babesia* sp., *Trypanosoma* species, *Anaplasma* sp., *Neospora caninum*,

6

Attorney Docket: I-2002.015 US  
Customer No.: 31846  
USSN: 10/527,771

*Staphylococcus aureus, Streptococcus agalactiae, Mycoplasma, E. coli, Enterobacter, Klebsiella, Citrobacter and Streptococcus dysgalactiae.*

43. (Previously presented) A diagnostic kit, comprising:
  - suitable detection means and
  - a nucleic acid sequence according to claims 30.
44. (Previously presented) A diagnostic kit, comprising:
  - suitable detection means and
  - a protein or immunogenic fragment thereof according to claim 34.
45. (Previously presented) A method of preventing or treating an infection caused by *Ostertagia ostertagi* in an animal, comprising:
  - administering an effective amount of the vaccine according to claim 36 to the animal.
46. (Previously presented) A method of preventing or treating an infection caused by *Ostertagia ostertagi* in an animal, comprising:
  - administering an effective amount of the vaccine according to claim 37 to the animal.

7

Attorney Docket: T-2002.015 US  
Customer No.: 31846  
USSN: 10/527,771

47. (Previously presented) A method of preventing or treating an infection caused by *Ostertagia ostertagi* in an animal, comprising:

administering an effective amount of the vaccine according claim 38 to the animal.

48. (Previously presented) A method of preventing or treating an infection caused by *Ostertagia ostertagi* in an animal, comprising:

administering an effective amount of the vaccine according claim 39 to the animal.

49. (Previously presented) A method of preventing or treating an infection caused by *Ostertagia ostertagi* in an animal, comprising:

administering an effective amount of the vaccine according claim 41 to the animal.